Amicus Therapeutics (FOLD) Scheduled to Post Earnings on Wednesday

Amicus Therapeutics (NASDAQ:FOLD) is scheduled to release its earnings data before the market opens on Wednesday, November 6th. Analysts expect Amicus Therapeutics to post earnings of $0.08 per share for the quarter. Amicus Therapeutics has set its FY 2024 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The firm had revenue of $126.67 million for the quarter, compared to analyst estimates of $121.21 million. During the same quarter last year, the firm posted ($0.15) EPS. The company’s revenue was up 34.0% on a year-over-year basis. On average, analysts expect Amicus Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amicus Therapeutics Stock Performance

Shares of FOLD stock traded up $0.19 during mid-day trading on Tuesday, reaching $11.52. The stock had a trading volume of 621,157 shares, compared to its average volume of 2,701,213. The firm’s 50 day simple moving average is $11.14 and its 200 day simple moving average is $10.59. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. Amicus Therapeutics has a one year low of $9.02 and a one year high of $14.57. The firm has a market cap of $3.42 billion, a PE ratio of -29.05 and a beta of 0.68.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Bank of America raised their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Jefferies Financial Group began coverage on Amicus Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $18.00 price objective for the company. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. cut their target price on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday, August 16th. Finally, Morgan Stanley cut their target price on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.13.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $9,398,532.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 22,500 shares of company stock worth $253,275. 2.20% of the stock is currently owned by insiders.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.